Review of bimekizumab in the treatment of psoriasis
Human Vaccines & Immunotherapeutics, 2022 Bimekizumab, a selective interleukin (IL) 17 inhibitor, is an emerging systemic treatment for moderate-to-severe psoriasis. Although IL-19, IL-22, and IL-36 are implicated in the pathogenesis of psoriasis, IL-17 drives the activation of these ...
Sindhuja Koppu +3 more
doaj +3 more sources
Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
Psoriasis: Targets and Therapy, 2022 Angelo Ruggiero, Luca Potestio, Elisa Camela Snr, Gabriella Fabbrocini, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, 80131, ItalyCorrespondence: Angelo Ruggiero, Section of ...
Angelo Ruggiero +2 more
exaly +2 more sources
Therapeutic Advances in Chronic Disease, 2023 Background: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17A and IL-17F, and is a promising drug for patients with moderate-to-severe plaque psoriasis.
Fang Hong, Jianjun Qiao, Yuqian Wang
exaly +2 more sources
Control of Inflammation and Sustained Improvements in Patient‐Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two‐Year Results From Two Phase 3 Studies [PDF]
ACR Open RheumatologyObjective To assess two‐year impact of bimekizumab on patient‐reported outcomes (PROs), and their association with objective measures of inflammation, in patients with psoriatic arthritis (PsA) who were biologic disease‐modifying antirheumatic drug ...
Laure Gossec +12 more
doaj +2 more sources
Cost–Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan [PDF]
Dermatology and TherapyIntroduction Psoriasis is a chronic, inflammatory skin disease that significantly impairs patients’ quality of life (QOL). Several biologics with varying mechanisms of action are approved for treating moderate-to-severe plaque psoriasis (PSO) in Japan ...
Atsuyuki Igarashi +6 more
doaj +2 more sources
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives
Patient Preference and Adherence, 2023 Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, Lluís Puig Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, SpainCorrespondence: Gemma Camiña-Conforto, Department of Dermatology, Hospital de la Santa Creu i Sant ...
Luis Puig +2 more
exaly +2 more sources
Journal of Dermatological Treatment, 2023 Aim This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis. Methods The PubMed, Web of Science, Cochrane Library, and Embase databases were systematically searched until November 20, 2022, to identify randomized controlled ...
Yuanyuan Qiu +3 more
exaly +2 more sources
Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials [PDF]
Frontiers in ImmunologyBackgroundScalp, nail, and palmoplantar psoriasis are termed “difficult-to-treat sites” owing to their unique anatomical features and therapeutic resistance, substantially impairing patient quality of life.
Shouxu Zhang +11 more
doaj +2 more sources
Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II [PDF]
Dermatology and TherapyIntroduction Hidradenitis suppurativa (HS) is a chronic skin disease that greatly affects patients’ health-related quality of life (HRQoL). Bimekizumab, a humanised monoclonal antibody that inhibits interleukin (IL)-17A and IL‑17F, has demonstrated ...
Steven Daveluy +11 more
doaj +2 more sources
Journal of Dermatological TreatmentPurpose of the article: The aim of this multicenter observational study is to report data from real world on the use of bimekizumab in patients aged ≥ 65 years with moderate-to-severe plaque psoriasis.
Martina Burlando +2 more
exaly +3 more sources